Oppenheimer raised the firm’s price target on TransMedics (TMDX) to $150 from $130 and keeps an Outperform rating on the shares. The firm notes that on June 2, OrganOx’s metra device had the “air transport” warning removed from its label. While this was largely expected, Oppenheimer did not identify the approval order on the FDA website until a client brought it to its attention yesterday. OrganOx continues to garner positive press from the OPO — Organ Procurement Organization — community, although the firm’s field checks on outcomes with metra continue to be relatively mixed. Oppenheimer’s view remains that metra should gain DCD liver share, not necessarily due to superior outcomes than TransMedics, but more so due to the frayed relationship between TransMedics and the OPO’s. TransMedics, to its credit, seems to be holding up reasonably well, as seen from the firm’s monthly tracker, Oppenheimer argues.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics price target raised to $145 from $125 at Piper Sandler
- TransMedics Group Holds 2025 Annual Shareholders Meeting
- TransMedics Group: Buy Rating Affirmed Amid Strategic Positioning and FDA Approval Prospects
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Strong Growth in Transplant Market Drives Buy Rating for TransMedics Group